Idexx laboratories announces second quarter results

Achieves second quarter revenue growth of 4% reported and 6.5% organic, driven by cag diagnostics recurring revenue growth of 4% reported and 7% organic, building on high prior year growth solid demand for diagnostic services and strong idexx execution support record second quarter premium instrument placements, driving 15% growth in global premium installed base delivers eps of $1.56, representing declines of 33% as reported and 30% on a comparable basis, including $0.72 per share impact from discrete r&d investments adjusts 2022 revenue guidance to 3% - 5.5% growth as reported and 5.5% - 8% organic. at midpoint, updated outlook reflects expectations for solid second half growth for cag diagnostics recurring revenues, similar to recent trends, adjusted for incremental benefits from higher pricing.
IDXX Ratings Summary
IDXX Quant Ranking